Cornercap Investment Counsel Inc. Sells 39,133 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Cornercap Investment Counsel Inc. lessened its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 48.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 41,458 shares of the biotechnology company’s stock after selling 39,133 shares during the period. Cornercap Investment Counsel Inc.’s holdings in CytomX Therapeutics were worth $49,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in CytomX Therapeutics during the 1st quarter worth about $57,000. US Bancorp DE acquired a new position in shares of CytomX Therapeutics during the third quarter worth approximately $40,000. XTX Topco Ltd grew its stake in shares of CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 48,033 shares during the last quarter. Forefront Analytics LLC increased its holdings in shares of CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX opened at $0.86 on Tuesday. CytomX Therapeutics, Inc. has a fifty-two week low of $0.84 and a fifty-two week high of $5.85. The firm has a market capitalization of $67.55 million, a P/E ratio of 5.35 and a beta of 1.06. The company’s 50 day simple moving average is $1.12 and its 200 day simple moving average is $1.42.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter in the prior year, the business posted $0.04 EPS. Sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.